Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine among Mexican children

Arch Med Res. 2012 Jul;43(5):402-5. doi: 10.1016/j.arcmed.2012.07.005. Epub 2012 Aug 3.

Abstract

Background and aims: Streptococcus pneumoniae infection continues to be a major source of morbidity and mortality in children in Mexico. The aim of this study was to evaluate the immune response to six serotypes in children <5 years of age after immunization with a 23-valent pneumococcal polysaccharide vaccine.

Methods: A prospective study was conducted among children aged from 18 months to 4 years. Pre- and postvaccination titers for the serotypes selected in this project demonstrate a substantial response among all age groups.

Results: We identified mild adverse events in 62% of the participants in this study. No serious adverse events were reported during the study.

Conclusions: Pneumococcal polysaccharide vaccine produced adequate immunogenicity in all age groups evaluated.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Antibodies, Bacterial / blood
  • Child, Preschool
  • Humans
  • Immunoglobulin G / blood
  • Infant
  • Pneumococcal Infections / prevention & control*
  • Pneumococcal Vaccines / administration & dosage*
  • Pneumococcal Vaccines / adverse effects
  • Pneumococcal Vaccines / immunology
  • Polysaccharides, Bacterial / administration & dosage*
  • Polysaccharides, Bacterial / adverse effects
  • Polysaccharides, Bacterial / immunology
  • Prospective Studies
  • Streptococcus pneumoniae / immunology*
  • Vaccination*

Substances

  • Antibodies, Bacterial
  • Immunoglobulin G
  • Pneumococcal Vaccines
  • Polysaccharides, Bacterial